Sartorius Stedim Biotech expanded its range of single-use membrane chromatography solutions with Sartobind Cassettes.
Sartorius Stedim Biotech has expanded its range of single-use membrane chromatography solutions with Sartobind Cassettes, a pod-like modular system for commercial applications in both capture and polishing. The cassettes offer the same flow path, bed heights (4 and 8 mm) and void volume ratios as Sartobind capsules, and are compatible with Q, S, STIC PA, and phenyl ligands. The new design goes beyond the previous 5-L size limitation for capsule formats, expanding the boundaries of membrane chromatography. Multiple cassettes, each with 0.8-L or 1.6-L membrane volume, can be set up in three different stainless-steel holders, resulting in maximum membrane volumes of 20, 50, or 100 L, respectively. Data demonstrates direct scalability from the 3-mL Sartobind nano capsule to 20.8 L (13 cassettes) in the Pilot Filter Holder. Pressure-flow performance and the shape of breakthrough curves are identical to the smaller capsule sizes, independent of the number of cassettes used. Set up can be accomplished within minutes, even at manufacturing scale, whether for capture applications or for flow-through removal of process contaminants.
The capture of large proteins such as viruses and virus-like particles, protein conjugates, and blood factors plays a key role in modern bioprocessing. The cassette system now enables large-scale bind-and-elute membrane chromatography for such targets.
“For the first time, the high binding capacity of membrane adsorbers can be used at almost any scale in commercial vaccine manufacture. Now, a 200 L Q anion exchange column for adenovirus capture can be easily replaced by a 20 L Q adsorber cassette system”, said Stefan Fischer-Frühholz, membrane chromatography expert at Sartorius Stedim Biotech, in a press release.
Source: SSB
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.